Identity
HGNC
LOCATION
1q21.3
LOCUSID
ALIAS
BCMP84,S100A15
FUSION GENES
Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 57402
MIM: 607986
HGNC: 18901
Ensembl: ENSG00000189334
Variants:
dbSNP: 57402
ClinVar: 57402
TCGA: ENSG00000189334
COSMIC: S100A14
RNA/Proteins
| Gene ID | Transcript ID | Uniprot |
|---|---|---|
| ENSG00000189334 | ENST00000344616 | Q9HCY8 |
| ENSG00000189334 | ENST00000368701 | Q9HCY8 |
| ENSG00000189334 | ENST00000368702 | Q9HCY8 |
| ENSG00000189334 | ENST00000476873 | Q9HCY8 |
Expression (GTEx)
Protein levels (Protein atlas)
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 38476086 | 2024 | LncRNA CTBP1-AS inhibits TP63-mediated activation of S100A14 during prostate cancer progression. | 1 |
| 38476086 | 2024 | LncRNA CTBP1-AS inhibits TP63-mediated activation of S100A14 during prostate cancer progression. | 1 |
| 36982421 | 2023 | Induction of Antimicrobial Protein S100A15 Expression by Oral Microbial Pathogens Is Toll-like Receptors-Dependent Activation of c-Jun-N-Terminal Kinase (JNK), p38, and NF-κB Pathways. | 1 |
| 36982421 | 2023 | Induction of Antimicrobial Protein S100A15 Expression by Oral Microbial Pathogens Is Toll-like Receptors-Dependent Activation of c-Jun-N-Terminal Kinase (JNK), p38, and NF-κB Pathways. | 1 |
| 35023052 | 2022 | Circ_0003221 Downregulation Restrains Cervical Cancer Cell Growth, Metastasis and Angiogenesis by Governing the miR-139-3p/S100A14 Pathway. | 5 |
| 35953822 | 2022 | Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. | 4 |
| 35023052 | 2022 | Circ_0003221 Downregulation Restrains Cervical Cancer Cell Growth, Metastasis and Angiogenesis by Governing the miR-139-3p/S100A14 Pathway. | 5 |
| 35953822 | 2022 | Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. | 4 |
| 33579599 | 2021 | S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. | 11 |
| 33890248 | 2021 | S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway. | 9 |
| 33579599 | 2021 | S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. | 11 |
| 33890248 | 2021 | S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway. | 9 |
| 31882495 | 2020 | A Clinicopathological Analysis of S100A14 Expression in Colorectal Cancer. | 1 |
| 32202693 | 2020 | Loss of S100A14 expression at the tumor-invading front correlates with poor differentiation and worse prognosis in oral squamous cell carcinoma. | 4 |
| 32483412 | 2020 | A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis. | 24 |
Citation
Dessen P
S100A14 (S100 calcium binding protein A14)
Atlas Genet Cytogenet Oncol Haematol. 2009-06-01
Online version: http://atlasgeneticsoncology.org/gene/50987/s100a14
